Test ID: 80786
Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization
Secondary ID 
A test code used for billing and in test definitions created prior to November 2011
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Useful For Suggests clinical disorders or settings where the test may be helpful
Diagnosis of latent Epstein-Barr virus infection
Supporting the diagnosis of nasopharyngeal carcinoma
Method Name A short description of the method used to perform the test
In Situ Hybridization Testing
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Aliases Lists additional common names for a test, as an aid in searching
EBV (Epstein-Barr Virus)
Epstein-Barr Virus (EBV) RNA Detection by In Situ Hybridization
Infectious Mononucleosis
IEBV
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Specimen Type: Formalin-fixed, paraffin-embedded tissue block; or 4 glass "positively charged" slides with formalin-fixed, paraffin-embedded tissue
Container/Tube: Surgical Pathology Packaging Kit (Supply T554)
Collection Instructions: Attach the green pathology address label included in the kit to the outside of the transport container.
Additional Information:
1. A pathology/diagnostic report and a brief history are required.
2. One slide will be stained with hematoxylin-and-eosin and retained.
Reject Due To Identifies specimen types and conditions that may cause the specimen to be rejected
| Hemolysis | NA |
| Lipemia | NA |
| Icterus | NA |
| Other | NA |
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
| Specimen Type | Temperature | Time |
|---|---|---|
| Tissue | Ambient | |
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Epstein-Barr virus (EBV) infection is associated with certain malignancies including nasopharyngeal carcinomas. Latent EBV infection of human tissues results in the expression of Epstein-Barr early RNA (EBER) in infected cells, which can be detected by in situ hybridization assays using oligonucleotide probes in paraffin sections.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
This test, when not accompanied by a pathology consultation request, will be answered as either positive or negative.
If additional interpretation/analysis is needed, request 5439 Surgical Pathology Consultation along with this test.
Interpretation Provides information to assist in interpretation of the test results
A positive reaction results in blue nuclear staining in tissue sections.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
A negative result does rule out Epstein-Barr virus (EBV) infection or associated malignancies.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Wu TC, Mann RB, Epstein JI, et al: Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. A morphologically distinctive target for detection of Epstein-Barr virus in formalin-fixed paraffin-embedded carcinoma specimens. Am J Pathol 1991;138:1461-1469
2. Randhawa PS, Jaffe R, Demetris AJ, et al: The systemic distribution of Epstein-Barr virus genomes in fatal post-transplantation lymphoproliferative disorders. An in situ hybridization study. Am J Pathol 1991;138:1027-1033
3. Chang KL, Chen YY, Shibata D, Weiss LM: Description of an in situ hybridization methodology for detection of Epstein-Barr Virus RNA in paraffin-embedded tissues, with a survey of normal and neoplastic tissues. Diagn Mol Pathol 1992;1:246-255
Method Description Describes how the test is performed and provides a method-specific reference
Epstein-Barr virus early RNA (EBER) in infected cells is detected by an in situ hybridization reaction with end-labeled oligonucleotide probes. (Chang KL, Chen YY, Shibata D, Weiss LM: Description of an in situ hybridization methodology for detection of Epstein-Barr virus RNA in paraffin-embedded tissues with a survey of normal and neoplastic tissues Diagn Mol Pathol 1992;1:246-255)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
88365
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
| Result ID | Reporting Name | LOINC Code |
|---|---|---|
| 18857 | Accession Number | N/A |
| 18858 | Referring Pathologist/Physician | 46608-6 |
| 18859 | Ref Path/Phys Address | In Process |
| 18860 | Material: | In Process |
| 18961 | Tissue: | 31208-2 |
| 18861 | Interpretation: | In Process |
| 18962 | Comment: | 48767-8 |
| 18862 | SP Signing Pathologist: | N/A |
| 18863 | *Previous Report Follows* | N/A |
| 18864 | Addendum: | 35265-8 |
| 19214 | Addendum Comment: | 22638-1 |
| 18865 | Addendum Pathologist: | 19139-5 |
External
link
PDF
document
Excel
document
Word
document